← Back to Search

Tremelimumab for Tumors

Phase 2
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. actual median study duration was 2.2 years.
Awards & highlights

Study Summary

This trial will provide access to the drug tremelimumab for patients who have previously received it in a clinical trial.

Eligible Conditions
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Kidney Cancer
  • Tumors
  • Melanoma and Other Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. actual median study duration was 2.2 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. actual median study duration was 2.2 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy Endpoints: Survival
Efficacy Endpoints: Tumor Status: Alive With Disease (AWD) or no Evidence of Disease (NED)
Safety Endpoints: Grade 3 or 4 Tremelimumab-related Adverse Events to Tremelimumab.
+2 more
Secondary outcome measures
Disease Free Survival

Side effects data

From 2023 Phase 2 trial • 37 Patients • NCT00378482
11%
Rash
8%
Pruritus
5%
Hypothyroidism
3%
Pulmonary Granuloma
3%
Urinary Tract Infection
3%
Prostate cancer
3%
Diarrhea
3%
Medical Device Complication
3%
Cholecystitis
3%
Sepsis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tremelimumab 15mg/kg

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Drug: CP-675,206 (Tremelimumab)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CP-675,206 (Tremelimumab)
2007
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,289 Previous Clinical Trials
288,620,161 Total Patients Enrolled
AstraZeneca AstraZenecaStudy DirectorAstraZeneca
81 Previous Clinical Trials
55,612 Total Patients Enrolled
Peter Langmuir, Dir.Medic.ScienceStudy DirectorAstraZeneca

Media Library

CP-675,206 (Tremelimumab) Clinical Trial Eligibility Overview. Trial Name: NCT00378482 — Phase 2
Colorectal Cancer Research Study Groups: 1
Colorectal Cancer Clinical Trial 2023: CP-675,206 (Tremelimumab) Highlights & Side Effects. Trial Name: NCT00378482 — Phase 2
CP-675,206 (Tremelimumab) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00378482 — Phase 2
~2 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top